Genpharmasec Limited's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, on August 11, 2026, along with Limited Review Reports. The Board meeting commenced at 03:00 p.m. on Tuesday, August 11, 2026, and concluded at 03:50 p.m. The financial statements, along with the Limited Review Reports, have been submitted to the stock exchange for record. The approval follows a thorough review by the company's Audit Committee, with the Board reviewing the financial performance for the quarter that concluded on June 30, 2026.
Genpharmasec's consolidated net profit declined 78.69% to ₹0.26 crore in the quarter ended June 2026, compared to ₹1.22 crore in the same period of the previous year. According to reports from Business Standard, this significant profit decline occurred despite the company achieving substantial revenue growth during the quarter. The latest financial results confirm this trend with consolidated profit before tax at ₹25.77 lakhs and standalone profit after tax of ₹156.96 lakhs for the quarter ended June 30, 2026. The company's basic and diluted earnings per share were reported at ₹0.03 each, reflecting the challenging profitability environment despite strong operational performance.
The company's sales rose dramatically by 312.87% to ₹49.71 crore in Q1 FY2026, as reported by Business Standard. This substantial increase in revenue from ₹12.04 crore in the corresponding quarter of the previous financial year represents a significant business expansion for the company. The latest financial results show consolidated revenue from operations at ₹500.83 crore and standalone revenue from operations at ₹447.84 lakhs for the quarter ended June 30, 2026. The company has provided detailed segment-wise information, highlighting performance across its various business segments including Pharmaceuticals, Laboratory Testing, and Manufacturing & Processing.
Operating profit margin (OPM) improved to 1.93% in the June 2026 quarter from 7.81% in the June 2025 quarter, as reported by Business Standard. The company's PBDT (Profit Before Depreciation and Tax) declined 38% to ₹0.93 crore from ₹1.51 crore year-on-year, while PBT (Profit Before Tax) fell 79% to ₹0.26 crore from ₹1.25 crore in the previous year's corresponding quarter. The latest financial results show consolidated profit before tax at ₹25.77 lakhs and standalone profit after tax of ₹156.96 lakhs, indicating continued operational challenges despite strong revenue performance. On a consolidated basis, total expenses were recorded at ₹498.26 crore leading to a profit before tax of ₹25.77 lakhs.
